» Articles » PMID: 35819710

Management of Lymphoma-associated Chylothorax by Interventional Radiology and Chemotherapy: a Report of Five Cases

Overview
Journal Int J Hematol
Specialty Hematology
Date 2022 Jul 12
PMID 35819710
Authors
Affiliations
Soon will be listed here.
Abstract

Chylous effusion is associated with lymphatic obstruction or leakage in mediastinal or abdominal lymph nodes, and is a rare but troublesome complication in patients with malignant lymphomas. Although there is no standard of care, it is often treated with simultaneous chemotherapeutic and non-chemotherapeutic interventions. Here, we describe the cases of five patients with lymphoma-associated chylothorax with the aim of clarifying an effective treatment strategy. All patients achieved a partial response or better for lymphoma. All patients underwent interventional radiology (IVR) procedures, including lymphangiography (LAG) and thoracic duct embolization (TDE). Complete resolution of chylothorax was eventually achieved by IVR procedures or pleurodesis in all patients. No patients experienced serious adverse events related to LAG/TDE. Treatment of chylous effusion required months for most patients (range: 0.2-4.8 months). Our data suggest that a combination of chemotherapy and LAG/TDE is effective for refractory lymphoma-related chylous effusion.

Citing Articles

Pulmonary Manifestations in Patients With Hematologic Malignancies: In Pursuit of an Accurate Diagnosis.

Alvarez-Payares J, Ribero Vargas D, Suarez E, Barrera-Correa D, Velez Aguirre J, Hernandez-Rodriguez J Cureus. 2025; 17(1):e77418.

PMID: 39949462 PMC: 11822728. DOI: 10.7759/cureus.77418.


Interventional treatment of refractory non-traumatic chylous effusions in patients with lymphoproliferative disorders.

Wagenpfeil J, Hoss K, Henkel A, Kutting D, Luetkens J, Feldmann G Clin Exp Med. 2024; 24(1):63.

PMID: 38554229 PMC: 10981590. DOI: 10.1007/s10238-024-01312-4.

References
1.
Staats B, ELLEFSON R, Budahn L, DINES D, Prakash U, Offord K . The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc. 1980; 55(11):700-4. View

2.
Doerr C, Allen M, Nichols 3rd F, Ryu J . Etiology of chylothorax in 203 patients. Mayo Clin Proc. 2005; 80(7):867-70. DOI: 10.4065/80.7.867. View

3.
Valentine V, Raffin T . The management of chylothorax. Chest. 1992; 102(2):586-91. DOI: 10.1378/chest.102.2.586. View

4.
Nair S, Petko M, Hayward M . Aetiology and management of chylothorax in adults. Eur J Cardiothorac Surg. 2007; 32(2):362-9. DOI: 10.1016/j.ejcts.2007.04.024. View

5.
Al-Zubairy S, Al-Jazairi A . Octreotide as a therapeutic option for management of chylothorax. Ann Pharmacother. 2003; 37(5):679-82. DOI: 10.1345/aph.1C265. View